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Temporal changes of cytokines and nitric oxide products in post-transplant, 18% in the second month, and 15% in
urine from renal transplant patients. the third to sixth months [4]. Immunosuppressive medi-
Background. Acute rejection and urinary tract infection (UTI) cations such as cyclosporine (CsA) can decrease the inci-both increase nitric oxide synthase (NOS) activity in urine from
dence of acute rejection in transplant patients. However,renal transplant patients. Also, with rejection, a regulatory inter-
these medications also can mask the signs and symptomsplay between nitric oxide (NO) and cytokines has been sug-
gested. Thus, measurement of the temporal changes of NOS of rejection, thus making the diagnosis of transplant re-
products and cytokines in urine will provide a strategy for the jection based on patient’s symptoms difficult [5]. In-
diagnosis of acute rejection and for its differentiation from UTI. flammatory mediators measured in the urine supernatantMethods. Soluble interleukins (ILs) and NOS-related prod-
collected from renal transplant patients might allow foructs, cyclic GMP (cGMP), nitrate, and nitrite were measured
in 192 urine samples consecutively collected from 13 patients early recognition of renal transplant rejection before
within the first three months of transplantation. Sixty-seven addi- damage to the graft results in renal dysfunction [6].
tional urine specimens were collected randomly from 24 patients Interleukin-2 (IL-2), IL-6, IL-8, IL-10, and tumor ne-
for follow-up analysis of the nitrate test.
crosis factor-a (TNF-a) affect T- or B-lymphocyte func-Results. Among patients who experienced rejection, the per-
tion [7] and have been found to change with transplant re-centage (%) binding of IL-2 increased within the first five days
(P 5 0.0004) after transplantation and one to five days prior jection [8, 9]. In a preliminary study, we found that urinary
to the clinical diagnosis (dx) of rejection (P 5 0.02). Tumor IL-2 levels are elevated with rejection but not with urinary
necrosis factor-a, IL-6, and IL-8 increased at the time of rejection tract infection (UTI; abstract; Saito et al, FASEB J 10:dx (P # 0.01). With UTI, IL-2 (P 5 0.01) decreased one to five
A701, 1996). Others have found that urine IL-6 levelsdays prior to dx, and IL-10 (P 5 0.003) increased one to five days
[10] and chemokine IL-8 levels [11] increase prior to theafter dx. Although cGMP and nitrate are dependent variables,
cGMP increased (P # 0.0009) with both rejection and UTI, and clinical diagnosis of acute rejection in renal transplant
nitrate increased (P 5 0.0001) with rejection and decreased (P 5 patients. Likewise, TNF-a is produced by mononuclear
0.0001) with UTI. Prior to formal dx (1 to 5 days), urine nitrate
cells during rejection [12]. Unlike IL-2, IL-6, IL-8, andclearly differentiated rejection (3004 to 7451 mmol/L) from UTI
TNF-a, IL-10 is decreased in kidney biopsies [8] and sera(90 to 885 mmol/L) and controls (1059 to 3235 mmol/L). The
additional 67 urines demonstrated that the sensitivity of the [13] from renal transplant patients with acute rejection.
nitrate test for rejection and UTI was 100%. With renal transplant rejection, a regulatory interplay
Conclusions. In renal transplant patients, specific temporal between nitric oxide (NO) and cytokines has been sug-changes in urine cytokine levels do occur with acute rejection
gested [14]. Three isoforms of NO synthase (NOS), endo-and UTI, but urine nitrate levels are the most precise at differ-
thelial NOS, neuroneal NOS, and inducible NOS (iNOS),entiating rejection from UTI.
produce NO from the guanidine nitrogen of l-arginine.
With inflammatory processes, including renal transplant
Acute rejection remains a significant risk factor for rejection, iNOS activity increases in several types of cells
renal transplant patients [1–3]. Fifty-four percent of re- including cells in urine [15, 16]. NO has a short half-life
jections have been reported to occur in the first month and is rapidly oxidized to nitrite and nitrate. In vivo, nitrite
is oxidized to nitrate, but in the presence of infection,
microorganisms convert nitrate to nitrite.Key words: nitrate, infection, graft rejection, urinary tract infection,
acute renal failure. Increased NO product formation results in activation
of guanylyl cyclase with an increase in cyclic GMP (cGMP)Received for publication December 16, 1999
[17]. cGMP initiates a cascade of protein phosphoryla-and in revised form February 15, 2000
Accepted for publication March 6, 2000 tions that lead to functional responses, including leuko-
cyte aggregation and adherence [18].Ó 2000 by the International Society of Nephrology
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Table 1. Clinical features of the patients included in the study
Rejection UTI
Patient Age Sex ESRD diagnosis Transplant (POD)
1 40 F Membranous GN LRT No No
2 56 M Membranous GN LURT No No
3 31 M Post-streptococcal GN LRT No No
4 53 M Renal vascular disease LRT 43 No
5 38 F Hypoplasia/obstruction CRT 34 No
6 44 F Diabetes mellitus LRT 39 18
7 59 F Polycystic disease CRT 34 37
8 39 M Chronic pyelonephritis LRT 8; 71 16
9 58 F Diabetes mellitus LRT No 0; 15; 60
10 28 F IgA nephropathy LRT No 57
11 52 M Reflux nephropathy LURT No 28
12 52 M Renal vascular disease CRT No 51
13 47 M Reflux nephropathy CRT No 22; 89
The average age of the 6 female (F) and 7 male (M) patients (pts.) is 45.9 6 10.2 (min. 5 28 and max. 5 59). Seven pts. had living-related donor transplants
(LRT), 2 had living-unrelated transplants (LURT), and 4 had cadaveric renal transplants (CRT). The diagnosis of rejection or urinary tract infection (UTI) was
given more than once to 3 pts. Patient 11 had cyclosporine toxicity on day 37. Patient 13 had an extrarenal infection, peritonitis, on postoperative day (POD) 45.
Abbreviations are: GN, glomerulonephritis; ESRD, end-stage renal disease.
In this study, we measured cytokine, nitrate/nitrite, Post-transplant diagnoses
cGMP, creatinine (Cr), and protein levels in urine pro- All graft rejection episodes were histologically con-
spectively collected during the first 90 days after renal firmed by graft biopsy. In this study, those patients having
transplantation. Values were correlated with the pa- a rejection episode experienced cellular rejection, charac-
tient’s urine culture results and with serum creatinine terized by an infiltration of mononuclear cells into the
(SCr). Our objective was to determine how these immuno- allograft with varying degrees of hemorrhage and edema.
logic parameters in urine change during the time sur- The patients who experienced rejection responded to
rounding renal transplant rejection, and to determine corticosteroids or OKT3. Urine culture results were re-
quired for the diagnosis of UTIs. Urine samples withwhich urine parameters differentiate acute rejection
mixed flora results were excluded unless the patient hadfrom renal transplant UTI.
a positive culture result (.105 organisms/mL) one day
before or after our urine collection date. CsA nephrotox-
METHODS icity was assumed when, after dose reduction, the SCr
concentration decreased within 24 hours. All serum andUrine sample isolation from two study populations
blood measurements, urine cultures, and histopathologi-
Urine was collected from renal transplant patients at
cal evaluations of kidney biopsies were done in the labo-
Yale/New Haven Hospital. A total of 256 urine samples ratories at the Yale/New Haven Hospital.
was collected by clean-catch or catheterization from two
different study populations. Population 1 (192 urine sam- Urine analysis
ples) consisted of 13 patients suffering from end-stage Urine samples were centrifuged at 2000 3 g (5 min),
renal disease (ESRD) who received living donor or ca- and aliquots of the supernatant were stored at 2808C
daver kidney transplants (Table 1). Urine was collected until analysis for protein, Cr, IL-2, percentage of IL-2
from patients before transplantation and during the first binding (IL-2B), IL-6, IL-8, IL-10, TNF-a, cGMP, and
90-days post-transplantation. Samples were collected at nitrate/nitrite.
least every other day during the first five days after trans- Urine protein concentrations were measured using bo-
plantation when the patient had an extended stay during vine g-globulin as a standard (Bio-Rad, Hercules, CA,
the first hospitalization, when the patient was seen in USA) [19]. Urinary creatinine (UCr) levels were mea-
the transplant clinic, and upon admission if the patient sured spectrophotometrically using the alkaline picrate
was rehospitalized. method [20].
A second population was studied to test the accuracy Tumor necrosis factor-a, IL-2, and IL-8 levels (Duo-
of our hypothesis developed from the results of the first 13 SeTs; Genzyme Diagnostics, Cambridge, MA, USA) and
patients. The second study population consisted of 24 IL-6 and IL-10 levels (matched antibody pairs; Endogen,
ESRD patients undergoing living donor or cadaver kidney Woburn, MA, USA) were measured in diluted urine
transplants. Sixty-seven urine samples were obtained ran- using an enzyme-linked immunosorbent assay (ELISA).
After thawing, urine was centrifuged (10,000 3 g, 5 min,domly within the first 90 days of renal transplantation.
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48C) and diluted in phosphate-buffered saline (PBS) con- $3000 mmol/L and low nitrate levels were defined as
#1000 mmol/L. The Fischer test statistically defined coin-taining 1% fatty acid free bovine serum albumin. Cyto-
kines were measured according to manufacturers’ rec- ciding transplant disease and urine nitrate levels.
ommendations, unless noted, in duplicate at one to three
urine dilutions. The sensitivities (pg/mL 6 SEM, N 5 3)
RESULTS
for cytokines were calculated as follows: TNF-a, 1.1 6
Post-renal transplant analysis of urine from0.3; IL-2, 4.8 6 3.0; IL-6, 9.1 6 1.0; IL-8, 7.0 6 0.7;
the initial patient populationand IL-10, 1.0 6 0.4. Recovery was determined for each
cytokine by adding a known amount (160 pg) of cytokine As shown in Table 1, in population 1, a total of six
acute rejection episodes occurred in 5 out of 13 renalto the urine being tested. Because recovery of IL-2 was
variable (75 6 26%; mean 6 SD), recovery was mea- transplant patients. Eleven UTIs occurred in 8 out of 13
of the transplant patients. CsA toxicity occurred in onesured on each sample, and values were corrected for
recovery. The decreased IL-2 recovery (75%) measured patient, and one of the patients was diagnosed with an
extrarenal infection. Acute rejection occurred at postop-signifies IL-2B (25%), most likely to the IL-2 receptor.
Recoveries for TNF-a (82 6 14%), IL-6 (100%), IL-8 erative day (POD) 38.2 6 8.3 (range from 8 to 71 days).
Four of the rejection episodes occurred between POD(100%), and IL-10 (100%) were not included in calcula-
tions for these cytokines. 34 to 43, and for the fifth patient, the rejection episodes
occurred 8 and 71 days after transplantation. UTIs oc-cGMP levels were determined in 1:50 dilutions of urine
supernatants using an [125I]-radioimmunoassay (Biomed- curred at POD 41.4 6 8.8 with four of these UTI episodes
occurring after day 50. The one patient with CsA toxicityical Technologies, Stoughton, MA, USA).
To determine endogenous urinary nitrite levels [21], was diagnosed on POD 37. Neither the patient with
CsA toxicity nor the patient with an extrarenal infectionGreiss reagent was added to urine or to sodium nitrite
standards and incubated for 15 minutes. Nitrite was mea- (diagnosed POD 45) exhibited significant, reportable dif-
ferences in their urinary cytokine, cGMP, or nitrate orsured spectrophotometrically at 546 nm. To determine
endogenous urinary nitrate levels, urinary nitrate and nitrite levels when compared with their baseline values.
nitrate standards were reduced to nitrite with bacterial
Comparison with preoperative resultsnitrate reductase (Sigma Chemical Co., St. Louis, MO,
USA), and nitrite levels were measured using the Greiss When the preoperative values of urine protein, UCr,
IL-2, IL-6, IL-8, IL-10, TNF-a, cGMP, and nitrate werereagent [21]. Since this assay measures both nitrite de-
rived from the reduction of nitrate and endogenous ni- compared with the three-month summed values from
control patients (transplant patients who never experi-trite, endogenous nitrite levels were subtracted to deter-
mine nitrate levels. enced UTI or rejection), the significant differences be-
tween the preoperative patients and control postopera-
Definitions of terms and data analysis tive patients were as follows: (1) Nitrate levels were
decreased in urine from pretransplant patients (845 6A self-controlled analysis of the urinary test values
with rejection or UTI was performed. That is, urine val- 178 mmol/L; range 275 to 1684; median 767) compared
with control post-transplant patients (2826 6 319 mmol/L;ues measured one to five days before the formal diagno-
sis of transplant rejection or UTI, on the day of formal range 512 to 10,501; median 2325, P 5 0.0001); and (2)
the broad range of IL-6 levels (1128 6 770 pmol/mL;diagnosis, and from one to five days after the formal
diagnosis were averaged by time frame and compared range 0 to 5356; median 63) in urine from pretransplant
patients was significantly (P 5 0.05) elevated comparedwith the average of the same patient’s baseline values.
The baseline urine samples were leukocyte (2) and col- with control post-transplant patients (147 6 74 pmol/mL;
range 0 to 2740; median 52).lected on days when the white blood cell (WBC) in the
patient’s serum was between 4000 and 10,000, and the Patients pretransplantation and post-transplantation
with SCr levels $10.0 mg/dL (N 5 11) had urine nitratepatient’s SCr value was one of the 20% lowest values.
Because it was not possible to assume that our data came levels #878 mmol/L, and only one nitrate level was
greater than 512 mmol/L (433 6 51 mmol/L; range 275from Gaussian populations, P values were calculated
using nonparametric analysis. The Friedman’s test was to 878; median 372).
used for repeated measures.
Early prediction of transplant rejection withFor predictive analysis of the nitrate test as a screening
the percentage of IL-2Btool for UTI and transplant rejection, nitrate was mea-
sured in 67 randomly collected urines from 24 transplant From the 13 transplant patients, 41 urine samples were
collected between PODs 1 through 5. All of the inflam-patients. The patients medical history from 0 to 5 days
after the date of urine collection was compared with the matory mediators (urine protein, UCr, IL-2, IL-6, IL-8,
IL-10, TNF-a, cGMP, and nitrate) were measured andurine nitrate levels. High nitrate levels were defined as
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Table 2. Urine cytokine levels 5 days before and 5 days after the diagnosis of renal transplant rejection
20% Baseline Days 21 to 25 Day 0 Days 11 to 15
(N 5 5, n 5 16) (N 5 5, n 5 7) (N 5 5, n 5 5) (N 5 5, n 5 5)
IL-2 pmol/mL 12.662.7 18.962.2 14.563.6 12.463.1
8.3 20.0 12.4 14.7
IL-2B % 18.264.0 35.267.3a 15.267.4 13.565.9b
16.3 29.0 6.9 15.6
IL-6 pmol/mL 150697.1 105642.3 151161219a 32.0621.6b
32.0 85.0 380 3.0
IL-8 pmol/mL 59.4614.5 65.6632.5 3056164a 45.2618.3b
39.0 35.0 217 58.0
IL-10 pmol/mL 9.262.6 15.766.1 15.066.0 6.562.2
4.4 6.9 12.0 6.7
TNF-a pmol/mL 11.861.6 18.763.0 30.066.3a 16.461.7a,b
10.6 17.4 24.8 18.2
The number of patients (N) who experienced rejection is 5 and 1 patient experienced 2 rejection episodes; n is the number of urine samples. IL-2B is the percentage
of IL-2 binding. Mean 6 SEM is reported above the median. “20% Baseline” values are results obtained from the 5 patients when their urine was leukocyte (2),
their serum WBC was between 4,000 and 10,000, and their serum Cr was one of the 20% lowest values. Days are defined as: 21 to 25, the 5 day period before
rejection; 0, the day that rejection was formally diagnosed; and 11 to 15, the 5 days after the formal diagnosis.
a Level increased compared to the “20% Baseline” (P , 0.05)
b Level decreased compared to peak (P , 0.05)
Table 3. Urine cytokine levels 5 days before and 5 days after the diagnosis of UTI in renal transplant patients
20% Baseline Days 21 to 25 Day 0 Days 11 to 15
(N 5 8, n 5 29) (N 5 8, n 5 10) (N 5 8, n 5 10) (N 5 8, n 5 11)
IL-2 pmol/mL 11.261.6 5.360.8b 12.963.1 9.362.7
8.5 1.8 11.8 6.4
IL-2B % 20.963.3 12.564.4 17.465.6 18.067.4
20.0 14.0 15.0 16.0
IL-6 pmol/mL 59.0625.6 32.7615.1 2946185 1936156
23.0 380 110 26.0
IL-8 pmol/mL 92.1622.8 68.6623.6 168668.3 160673.3
35.5 19.5 87.5 94.5
IL-10 pmol/mL 9.862.1 6.164.8 5.462.3 21.962.3a
4.6 5.9 5.4 17.0
TNF-a pmol/mL 11.261.3 13.762.3 14.862.5 10.662.6
9.6 11.5 12.8 11.4
The number of patients (N) who experienced UTI is 8 and 2 patients experienced more than one UTI. n is the number of urine samples. IL-2B is the percentage
of IL-2 binding. Mean 6 SEM is reported above the median. “20% Baseline” values are results obtained from the 8 patients when their urine was leukocyte (2),
their serum WBC was between 4,000 and 10,000, and their serum Cr was one of the 20% lowest values. Days are defined as: 21 to 25, the 5 day period before
UTI. 0, the day that the UTI was formally diagnosed; 11 to 15, the 5 days after the formal diagnosis.
a Level increased compared to “20% Baseline” (P , 0.05)
b Level decreased compared to peak (P , 0.05)
compared between patients who experienced rejection with the patient’s baseline values (Tables 2 and 3). Each
patient served as his or her own control. The significantand patients who did not. The significant difference be-
changes in temporal patterns are summarized as follows:tween these two groups of patients was the urinary IL-2
Similar to the IL-2B elevation during the first five daysrecovery or, in other words, the percentage of IL-2B (P 5
of transplantation, IL-2B (%) was elevated one to five0.002). Within the first five days after transplantation,
days (1.9-fold) prior to the formal diagnosis of transplantpatients who later experienced an episode of rejection
rejection. IL-2 levels were decreased one to five dayshad IL-2B levels of 30.2 6 5.0% (range 0.0 to 56.0;
(2.1-fold) prior to the diagnosis of UTI, but on the daymedian 30.1), and patients who did not experience rejec-
of diagnosis of UTI, IL-2 levels were comparable to thetion had IL-2B levels of 11.9 6 13.4% (range 0.0 to 45.2; baseline values. On the day of the formal diagnosis of
median 8.0). transplant rejection, IL-6 (10-fold), IL-8 (5.1-fold), and
TNF-a (2.5-fold) were elevated compared with the pa-Cytokine profile in urine from renal
tient’s baseline values. After the diagnosis of transplant
transplant patients rejection, the elevated levels of IL-2B, IL-6, IL-8, and
Cytokine levels were analyzed for the five days prior TNF-a decreased. One to five days after the diagnosis
to (days 25 to 21) and after (days 1 to 5) transplant of UTI, IL-10 levels increased 2.2-fold compared with
baseline levels.rejection (day 0) or transplant UTI (day 0) and compared
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Table 4. Urine nitrate and cyclic GMP levels 5 days before and 5 days after the diagnosis of rejection or UTI in renal transplant patients
20% Baseline Days: 21 to 25 Day 0 Days 11 to 15
(N 5 5, n 5 16) (N 5 5, n 5 7) (N 5 5, n 5 15) (N 5 5, n 5 5)
Rejection
cGMP lmol/L 0.3860.07 1.2160.61a 1.1360.12a 0.3760.12
0.37 0.80 1.06 0.48
Nitrate lmol/L 18786198 45306676a 23446169a 1853663.0
1891 3839 2364 1875
Infection
cGMP lmol/L 0.4060.05 0.3360.07 1.0360.21a 0.5060.07
0.38 0.29 0.84 0.57
Nitrate lmol/L 18576128 561677.4b 1027640.4b 14706210
1792 581 1039 1697
The median is shown in italics.
a Level increased compared to “20% Baseline” value (P , 0.05)
b Level decreased compared to “20% Baseline” value (P , 0.05)
When comparing cytokine levels of patients with
transplant rejection and patients with transplant UTI,
(1) there were no significant differences between 20%
baseline values or the values from days 1 through 5 after
the diagnosis. (2) One to five days prior to rejection or
UTI diagnosis, IL-2 and IL-2B were 3.6- and 2.8-fold
higher, respectively, with rejection than with UTI. (3)
On day 0, TNF-a levels were twofold higher with rejec-
tion than with UTI.
cGMP, nitrate, and nitrite levels with renal
transplant rejection and UTI
With UTI, cGMP levels increased compared with the
baseline levels but, unlike rejection levels, not until the day
of diagnosis (Table 4). One to five days after the diagnosis
of UTI, cGMP levels decreased to levels comparable to
controls (Table 4).
Unlike cGMP levels, nitrate levels decreased one to
five days prior to UTI compared with baseline levels
(Table 4). Like cGMP levels, nitrate levels were elevated
one to five days prior to the diagnosis of rejection (Table
4). When nitrate levels measured at days 21 to 25 were
compared between patients with rejection and UTI, they
Fig. 1. A comparison of urine nitrate levels one to five days prior tonever overlapped (Fig. 1). At day 0, the nitrate levels
the formal diagnosis of rejection (r) or urinary tract infection (hx ;between rejection and UTI remained different with no UTI), at the time of formal diagnosis, and one to five days after the
overlap. On days 1 to 5 after diagnosis, nitrate values formal diagnosis. From five days before to the time of formal diagnosis,
there was no overlap between nitrate levels measured in urine fromfor rejection and UTI remained significantly different,
patients with rejection and patients with UTI.although there was some overlap (Fig. 1).
Nitrite was positive only with UTI. A positive nitrite test
was defined as a visible color change to pink. Eight patients and 1.7 6 0.1 mg/dL (range, 1.2 to 2.8; median, 1.6),
had 11 episodes of UTI, and of those 11 episodes of UTI, respectively. Both the SCr and UCr levels remained ele-
nitrite was positive five times. Nitrite was never falsely vated one to five days after the diagnosis.
positive, but falsely negative 6 out of 11 times (54.5%). With UTI, UCr was decreased on the day of diagnosis
(19.8 6 3.4 g; range 7.7 to 40.9; median 15.0) when com-
Serum creatinine versus urinary creatinine pared with baseline (39.6 6 3.7 g; range 9.9 to 74.5;
With kidney transplant rejection, both UCr (59.7 6 15.7 g; median 42.8), but at no other time were urine Cr levels
range 21.7 to 128; median 34.2) and SCr (2.7 6 0.3 mg/dL; with UTI significantly different from baseline levels.
range 1.2 to 3.3; median 3.0) levels increased on the day When compared with baseline values, SCr levels did not
of diagnosis compared with 20% baseline values, which significantly change before, on the day of diagnosis, or
after the diagnosis of UTI.were 35.3 6 4.0 mg/dL (range, 13.1 to 53.4; median, 42.5)
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Table 5. Nitrate urine levels for renal transplant UTI and infrequently associated with previously recognized clinical
rejection screening
signs of rejection. A decrease in urine volume is associated
Urine nitrate level lmol/L with only 28% of rejection episodes, and fever is associ-
Diagnosis #1000 1001–2999 $3000 Total ated with only 31% of rejection episodes [4]. In addition,
differentiating renal transplant rejection from UTI, a com-Rejection 0 3 18 21
UTI 11 4 0 15 mon bacterial infection in renal transplant patients, can be
No rejection or UTI 0 31 0 31 difficult [24]. This study not only verifies that inflammatory
Total 11 38 18 67 mediators in urine change after renal transplantation,
Nitrate was measured in 67 urine samples. The nitrate levels were then corre- but also shows which mediators in urine are significant
lated with the transplant patients’ formal diagnosis. UTI is urinary tract infection. for the prediction and for the early diagnosis of trans-
plant UTI or rejection. Preoperatively, in renal failure
patients, urine IL-6 levels are increased, and urine nitrate
levels are decreased. When evaluated within the first fiveUrine protein with transplant rejection and
days of transplantation, the percentage of bound IL-2 istransplant infection
increased in urine from renal transplant patients at risk
When patients experienced rejection or UTI (days 25 for acute rejection. For early detection of post-transplant
to 21, day of diagnosis, or days 1 to 5), there were no disease states, urine nitrate levels are elevated with renal
significant changes in their urine protein levels when transplant rejection and decreased with UTI, usually one
compared with baseline protein levels (P 5 0.3). to five days prior to the currently used methods.
We found increased urine IL-6 and decreased urineFurther diagnostic analysis of nitrate levels in urine
nitrate levels in renal failure patients preoperatively.from renal transplant patients
IL-6 mRNA [25] and IL-6 protein expression [26] are
Because there was no overlap between nitrate levels increased in peripheral blood mononuclear cells from
in renal transplant patients with rejection or UTI, further patients undergoing either hemodialysis or continuous
evaluation of nitrate as a differential screening test was ambulatory peritoneal dialysis. Grabowski et al showed
done with 67 urine samples randomly obtained within that the dietary intake of nitrate has no significant influ-
the first 90 days of renal transplantation (Table 5). Rejec- ence on the fasting morning urinary nitrate:creatinine
tion was defined as a nitrate level $3000 mmol/L and a ratio [27]. However, this study showed that urinary ni-
UTI was defined as a level #1000 mmol/L. The urine trate levels are significantly decreased with a SCr $10.
nitrate levels and formal diagnosis of rejection or UTI Nitrate and nitrite are excreted by the kidney, and thus,
statistically coincided (P , 0.01). One hundred percent renal function and clearance should be considered if they
of the patients (18 out of 18) with a nitrate level $3000 are intended to be used as markers of NO production.
mmol/L were diagnosed with rejection. One hundred Mean plasma nitrate is approximately threefold to four-
percent of the patients (11 out of 11) with nitrate levels fold higher than normal in patients with renal disease
#1000 mmol/L were diagnosed with a UTI. Three of the prior to dialysis [28]. Endogenous inhibitors of NOS,
21 patients (14%) diagnosed with rejection and 4 of the such as symmetrical and asymmetrical dimethyl arginine,
15 patients (27%) with UTI had nitrate levels between are increased in patients with low glomerular filtration
1001 and 2999 mmol/L. If the transplant patient did not rates, and thus, NOS products such as nitrate may be
have rejection or UTI, their urine nitrate level was always decreased in the patient’s urine [28].
between 1001 and 2999 mmol/L. When measured within the first five days after renal
transplantation, a decreased recovery of IL-2 in urine is
predictive of renal transplant rejection. Decreased IL-2
DISCUSSION recovery signifies binding of IL-2, and IL-2 binding is
Early recognition and treatment of acute rejection most likely caused by increased expression of the IL-2
may improve the outcome of renal transplant patients receptor. The soluble IL-2 receptor appears to be ex-
[22, 23]. As described in a study evaluating kidney trans- creted intact in urine and has been described to originate
plantation in rats, early recognized changes of rejection from serum, from urine cells originating in the bladder,
are reversible. However, unrecognized, advanced re- and from a variety of cell types excreted by the trans-
jecting grafts are irreversibly damaged [22]. Likewise, planted kidney [10, 29]. Casiraghi et al reported that the
with early treatment of acute rejection following lung urinary levels of the IL-2 receptor are increased three
transplantation, the severity of the acute rejection event days after renal transplantation in patients who later
is reduced, and the development of chronic rejection is experience one or more episodes of acute rejection and
prevented [23]. Furthermore, delayed treatment of acute that IL-2 receptor levels are not elevated in transplant
rejection can stimulate the onset of chronic rejection [23]. patients who do not develop rejection [10].
Casiraghi et al also found that increases in IL-6 levelsWith current treatment measures, rejection episodes are
Smith et al.: Urinary cytokines and NO after renal transplantation 835
during the first five days after transplantation were spe- between the two diseases. Recently, Vandivier et al
cific for transplant rejection. In the present study, al- found that urinary nitrate/nitrite levels are more sensitive
though IL-6 levels were not elevated prior to rejection, to changes in NO production than urinary or plasma
they were increased in urine at the time of biopsy docu- cGMP, plasma nitrate/nitrite, or plasma S-nitrosothiol
mented rejection. In accord with our findings, Di Paolo [41]. Also, increases in exhaled NO paralleled increases
et al found that IL-6 expression increases with acute in urinary nitrate/nitrite [41]. Thus, although the results
kidney transplant rejection and is localized chiefly to of Vandivier et al correlate with ours, further studies are
proximal tubular cells and monocytes/macrophages [30]. needed to compare urine NO product levels between
Along with urine IL-6 levels, urine IL-8 and TNF-a patients with transplant rejection and patients with other
levels also were elevated significantly on the day of diag- inflammatory disease processes.
nosis of renal transplant rejection. IL-6 and IL-8 can Although most workers have found elevated serum
be induced in parallel in response to inflammation and nitrate levels with transplant rejection or graft versus
infection [31, 32]. With acute renal transplant rejection, host disease, there has been less agreement with infec-
IL-8 levels in urine are elevated [14, 34], and IL-8 staining tion. With infection, nitrate has been reported to be
of both interstitial mononuclear and tubular epithelial elevated [42] or unchanged [43]. We found that urine
cells from the kidney biopsy specimens is positive nitrate levels were decreased with UTIs and that the
[33, 34]. TNF-a also is a mediator of inflammatory and only time urine nitrite levels (5 out of 11) in transplant
immune functions and previously has been shown to patients were increased was with UTIs. Urine nitrate
increase with renal transplant rejection [12]. can be reduced to nitrite by bacterial and mammalian
With evaluation of UTIs and cytokines, it was found metabolic pathways. Perhaps the lower levels of nitrate
that IL-2 levels were decreased significantly one to five with UTI result from the increased synthesis of other
days prior to the diagnosis of UTI, while IL-10 levels nitrogen-containing molecules [44]. Bacterial enzymes
were elevated significantly one to five days after the can convert nitrate to nitrite and to other nitrogen-con-
diagnosis of UTI. In a preliminary study, we found that taining molecules, including urea and ammonia. The
urine IL-2 levels are elevated with rejection but not with widespread occurrence of nitrate reductase activity in
UTI (abstract; Saito et al, FASEB J 10:A701, 1996). bacteria means that nitrite is produced endogenously at
Agents used to treat rejection, such as CsA and methyl- sites populated by large numbers of bacteria, including
prednisolone, do inhibit IL-2 production in peripheral the urinary bladder.
blood mononuclear cells [35], but are also associated Urine inflammatory markers display significant changes
with the onset of UTIs [24]. Thus, antirejection treatment with renal transplantation. Nitrate levels are increased
may decrease urine IL-2 levels but increase the incidence in the five days prior to the diagnosis of transplant rejec-
of UTIs. In contrast to the decreased IL-2 levels with tion and decreased prior to the diagnosis of UTI, and
UTI, IL-10 was elevated. Other investigators have found there is no overlap between the nitrate values with the
elevated serum IL-10 with infection, specifically Epstein- two transplant-related disease processes. With evalua-
Barr virus reactivation [36]. tion of nitrate levels in 67 randomly collected urines,
Urinary creatinine and urinary protein also were eval- nitrate levels were greater than or equal to 3000 mmol/L
uated as UTI and rejection identifying factors. One unex- only in urine from patients diagnosed with rejection and
pected finding was that UCr levels were significantly ele- less than or equal to 1000 mmol/L only in urine from
vated with transplant rejection. The reliability of UCr patients diagnosed with UTI (Table 5). Patients without
measurements may be diminished by the variability in rejection or UTI had urine nitrate values between 1000
tubular secretion of Cr [37–39]. Tubular secretion of Cr and 3000 mmol/L.
tends to increase proportionally with declining levels of Factors related to NO, including nitrate, cGMP, and
renal function. Also, high temperatures and low pH can cytokines, are found in the urine supernatant. Although
promote the conversion of creatine to Cr in urine [39]. renal transplant rejection and UTI have significant ef-
Although the protein in urine has been found to be fects on these urine components, only urine nitrate levels
an early predictor of delayed graft function and acute change significantly prior to renal transplant rejection
rejection [40], we did not find a significant difference and UTI. In addition, this change in nitrate differentiates
between urinary protein levels in the five-day time frame. rejection from UTI, allowing for early biopsy and treat-
We found that nitrate levels in urine are valuable for ment of the transplant patients.
the early diagnosis of renal transplant rejection and for
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